Antibody Information
General Information of This Antibody (ID: ANTI0JOGEB)
| Antibody Name | Anti-CDH17 antibody |
|||||
|---|---|---|---|---|---|---|
| Antigen Name | CDH17 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
AMT-676 [Phase 2]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have unresectable advanced solid tumors (e.g., colorectal, gastric, or pancreatic cancers), ECOG 0-1, and adequate organ function. Key exclusions include prior ADC/targeted therapy, CNS metastasis, active infections, severe cardiac/respiratory conditions, recent major surgery/radiation, pregnancy, or concurrent investigational treatment.
Click to Show/Hide
|
||||
| Administration Dosage |
Participants will receive AMT-676 administered intravenously. Participants will be observed for first instance of dose limiting toxicities (DLT).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06400485 | Clinical Status | EARLY_PHASE1 | ||
| Clinical Description |
First-in-Human, Phase 1 Study of AMT-676 in Patients With Advanced Solid Tumors
|
||||
| Primary Endpoint |
The study focuses on determining the Recommended Phase 2 Dose (RP2D) and Maximum Tolerated Dose (MTD) based on dose-limiting toxicities (DLTs) and safety profiles, with assessments within 30 days post-dosing. Adverse events will also be evaluated using CTCAE v5.0 for severity and incidence.
|
||||
| Other Endpoint |
Pharmacokinetic parameters such as Cmax, Tmax, AUC, and t1/2 of AMT-676 will be measured within 30 days post-dosing. Immunogenicity will be assessed via anti-drug antibody (ADA) levels, while efficacy endpoints include ORR (CR/PR), DCR (CR/PR/SD), and PFS per RECIST v1.1.
|
||||